Portfolio

We are enabling companies to turn their boldest ambitions into world-changing breakthroughs in healthcare and technology.

Portfolio

Spotlights Portfolio List

Portfolio List

Develops innovative embolotherapy using inorganic polymer microspheres for hypervascular tumors.
Uses genome-wide methylation analysis for earlier, precise cancer and morbidity detection.
Developing Amber-UI neuromodulation therapy using Picostim for urinary incontinence.
Developing innovative neuromodulation technology to treat large disease populations.
Develops innovative orthopedic solutions to restore patient mobility and enhance surgical outcomes.
Develops and commercializes novel digital programmable hearing aid solutions for China.
Developed a CE-Marked product for improving dialysis access surgery.
Develops and commercializes high-quality hyaluronic acid (HA) based products for the Chinese market.
Develops therapies for epilepsy and other neurological disorders with neural implant technology.
Redefining PCR with single-molecule precision and category-defining sensitivity.
Provides compact, affordable flow cytometry instruments with high multiplexing capabilities.
NASDAQ: CTBK
Developing innovative treatments for eye diseases and vision disorders.
SHA: 688050
Hemostatic product manufacturer in China.
Develops and produces insulin pumps.
Manufactures, develops, and commercializes high quality, affordably priced cardiovascular and general surgery medical devices.
Manufactures and markets minimally invasive interventional therapy medical devices in the field of ENT, cardiovascular and others.
Promotes the development of cervical cancer screening and prevention in China.
Developing precision diagnostic solutions for cell analysis and research.
Providing quality medical equipment and supporting healthcare professionals and patients.
Developing advanced DNA sequencing solutions though genomics technology.
NASDAQ: OMIC
Developing diagnostic and imaging solutions for healthcare providers.
Developing MRI-guided radiation therapy systems for cancer treatment.
NASDAQ: VRAY
Developing minimally invasive treatments for benign prostatic hyperplasia.
The companies identified do not represent all the companies purchased, sold, or recommended for portfolios advised by F-Prime.